Section Arrow
FOLD.NASDAQ
- Amicus Therapeutics
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 8.59
+0.07 (+0.82%)
Day High 
8.6 
Prev. Close
8.52 
1-M High
9.5 
Volume 
2.46M 
Bid
8.04
Ask
8.8
Day Low
8.494 
Open
8.54 
1-M Low
8.4 
Market Cap 
2.62B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.89 
20-SMA 8.96 
50-SMA 9.3 
52-W High 12.65 
52-W Low 8.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.18/0.35
Enterprise Value
3.05B
Balance Sheet
Book Value Per Share
0.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
528.30M
Operating Revenue Per Share
1.21
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants;a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.